TOPROL-XL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TOPROL-XL (TOPROL-XL).

How it works

Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.

What the body does with it

Metabolism	Primarily metabolized by CYP2D6; minor pathways include dealkylation and glucuronidation.
Excretion	Metoprolol is extensively metabolized in the liver via CYP2D6; less than 5% of an oral dose is excreted unchanged in urine. The metabolites, primarily α-hydroxymetoprolol, are excreted renally. Biliary/fecal excretion accounts for less than 5% of the dose.
Half-life	Terminal elimination half-life is 3-7 hours, but in CYP2D6 poor metabolizers (about 7% of Caucasians) it can extend up to 8-10 hours. This variability is clinically relevant for dose titration.
Protein binding	Approximately 12% bound to plasma proteins (mainly albumin). This low binding is clinically insignificant for drug interactions.
Volume of Distribution	Volume of distribution is 4-5 L/kg, indicating extensive extravascular distribution. This is consistent with its lipophilic nature and ability to cross the blood-brain barrier.
Bioavailability	After oral administration, bioavailability is approximately 50% due to extensive first-pass hepatic metabolism. The extended-release formulation (TOPROL-XL) has similar bioavailability but provides more sustained plasma concentrations.
Onset of Action	Oral: 1 hour for reduction of exercise-induced tachycardia; maximal effect on heart rate occurs within 2-8 hours depending on dose and formulation (extended-release TOPROL-XL). Intravenous: immediate (5-10 minutes).
Duration of Action	After oral administration of extended-release formulation, the effect on heart rate and blood pressure lasts approximately 24 hours. Immediate-release tablets require twice-daily dosing. Duration may be longer in CYP2D6 poor metabolizers.

Classification & Brands

Dosing & administration

100 to 400 mg orally once daily starting at 100 mg/day; maximum 400 mg/day.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	No dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, reduce dose by 50% or use alternative.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce initial dose by 50% and titrate cautiously; Child-Pugh Class C: avoid use or use extreme caution with 50% dose reduction.
Pediatric use	Not FDA-approved for pediatric patients; limited data suggest initial 1 mg/kg/day orally once daily, maximum 2 mg/kg/day or 200 mg/day.
Geriatric use	Initiate at lower doses (25-50 mg orally once daily) and titrate slowly; monitor heart rate and blood pressure closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TOPROL-XL (TOPROL-XL).

Breastfeeding	Metoprolol (active ingredient) is excreted in breast milk at low levels (M/P ratio approximately 1.2). Limited data suggest no adverse effects in breastfed infants at maternal therapeutic doses, but infant should be monitored for signs of beta-blockade (e.g., bradycardia, hypotension).
Teratogenic Risk	First trimester: Limited human data; animal studies show no major malformations at clinically relevant doses. Second and third trimesters: Associated with fetal bradycardia, intrauterine growth restriction, and neonatal hypoglycemia due to beta-blockade. Risk of preterm labor may be increased.

Warnings & precautions

■ FDA Black Box Warning

Do not abruptly discontinue; taper dose over 1-2 weeks to avoid exacerbation of angina, MI, or ventricular arrhythmias.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Cardiogenic shock","Decompensated heart failure","Sick sinus syndrome (without pacemaker)","Second- or third-degree AV block (without pacemaker)","Severe bradycardia","Hypersensitivity to metoprolol or any component"]

Clinical Precautions

Precautions

["Exacerbation of angina and MI upon abrupt withdrawal","Heart failure (may worsen; monitor for signs of fluid retention)","Bradycardia and heart block","Bronchospasm in patients with asthma/COPD (use with caution)","Peripheral vascular disease (may aggravate symptoms)","Thyrotoxicosis (may mask tachycardia)","Diabetes (may mask hypoglycemia symptoms)","Renal impairment (dose adjustment may be needed)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TOPROL-XL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TOPROL-XL (TOPROL-XL).

How it works

Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.

What the body does with it

Metabolism	Primarily metabolized by CYP2D6; minor pathways include dealkylation and glucuronidation.
Excretion	Metoprolol is extensively metabolized in the liver via CYP2D6; less than 5% of an oral dose is excreted unchanged in urine. The metabolites, primarily α-hydroxymetoprolol, are excreted renally. Biliary/fecal excretion accounts for less than 5% of the dose.
Half-life	Terminal elimination half-life is 3-7 hours, but in CYP2D6 poor metabolizers (about 7% of Caucasians) it can extend up to 8-10 hours. This variability is clinically relevant for dose titration.
Protein binding	Approximately 12% bound to plasma proteins (mainly albumin). This low binding is clinically insignificant for drug interactions.
Volume of Distribution	Volume of distribution is 4-5 L/kg, indicating extensive extravascular distribution. This is consistent with its lipophilic nature and ability to cross the blood-brain barrier.
Bioavailability	After oral administration, bioavailability is approximately 50% due to extensive first-pass hepatic metabolism. The extended-release formulation (TOPROL-XL) has similar bioavailability but provides more sustained plasma concentrations.
Onset of Action	Oral: 1 hour for reduction of exercise-induced tachycardia; maximal effect on heart rate occurs within 2-8 hours depending on dose and formulation (extended-release TOPROL-XL). Intravenous: immediate (5-10 minutes).
Duration of Action	After oral administration of extended-release formulation, the effect on heart rate and blood pressure lasts approximately 24 hours. Immediate-release tablets require twice-daily dosing. Duration may be longer in CYP2D6 poor metabolizers.

Classification & Brands

Dosing & administration

100 to 400 mg orally once daily starting at 100 mg/day; maximum 400 mg/day.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	No dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, reduce dose by 50% or use alternative.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce initial dose by 50% and titrate cautiously; Child-Pugh Class C: avoid use or use extreme caution with 50% dose reduction.
Pediatric use	Not FDA-approved for pediatric patients; limited data suggest initial 1 mg/kg/day orally once daily, maximum 2 mg/kg/day or 200 mg/day.
Geriatric use	Initiate at lower doses (25-50 mg orally once daily) and titrate slowly; monitor heart rate and blood pressure closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TOPROL-XL (TOPROL-XL).

Breastfeeding	Metoprolol (active ingredient) is excreted in breast milk at low levels (M/P ratio approximately 1.2). Limited data suggest no adverse effects in breastfed infants at maternal therapeutic doses, but infant should be monitored for signs of beta-blockade (e.g., bradycardia, hypotension).
Teratogenic Risk	First trimester: Limited human data; animal studies show no major malformations at clinically relevant doses. Second and third trimesters: Associated with fetal bradycardia, intrauterine growth restriction, and neonatal hypoglycemia due to beta-blockade. Risk of preterm labor may be increased.

Warnings & precautions

■ FDA Black Box Warning

Do not abruptly discontinue; taper dose over 1-2 weeks to avoid exacerbation of angina, MI, or ventricular arrhythmias.